Arch Therapeutics, Inc. (ARTH)
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 0.1608
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- 0.00
- Turnover Ratio
- --
News
- StockTitan · Mar 24 at 12:13 AM
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial | ACHFF Stock News
- GlobeNewswire · Mar 20 at 06:05 AM
Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
- MorningStar · Feb 26 at 12:10 PM
Arthrex Releases TightRope® SB All-Suture Implant for ACL Fixation
- Unusual Whales · Feb 25 at 02:03 AM
Arthex Biotech's ATX-01 promising for DM1 per American Journal of Human Genetics; miR-23b target shows benefits.
